Gilead Sciences, Inc. (GILD) March 07, 2012 4:30 pm ET Executives Susan Hubbard - Vice President of Investor Relations Norbert W. Bischofberger - Chief Scientific Officer and Executive Vice President of Research & Development Paul Sax - Andrew Cheng - Senior Vice President of Development Operations Analysts Michael E. Ulz - JP Morgan Chase & Co, Research Division Mark J. Schoenebaum - ISI Group Inc., Research Division Matthew Roden - UBS Investment Bank, Research Division Yaron Werber - Citigroup Inc, Research Division Sapna Srivastava - Goldman Sachs Group Inc., Research Division Brian Abrahams - Wells Fargo Securities, LLC, Research Division Robyn Karnauskas - Deutsche Bank AG, Research Division M. Ian Somaiya - Piper Jaffray Companies, Research Division PresentationOperator
Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Conference Call. My name is Stacey, and I will be your conference operator for today. [Operator Instructions] As a reminder, this conference call is being recorded today, March 7, 2012. I would now like to turn the call over to Susan Hubbard, Vice President of Investor Relations. Please go ahead. Susan Hubbard Thank you, Stacey. And good afternoon, everyone. Thank you for joining us today to discuss the 48-week results from Study 102, the pivotal Phase III study of our Quad drug head-to-head versus ATRIPLA. You can find the press release detailing the study results, as well as a link to the slides presented here today on our website at gilead.com. We have Dr. Paul Sax with us today, the lead investigator from the study. Dr. Sax will recap the presentation he just gave here in Seattle at the Conference on Retroviruses and Opportunistic Infections. Dr. Sax's comments today will reflect his own conclusions, opinion and analysis and do not necessarily reflect Gilead's conclusions, opinions, and analyses. We're also joined today by our Executive Vice President of R&D, Norbert Bischofberger; and Andrew Cheng , our Senior Vice President of HIV Therapeutic and Development Operations. Dr. Sax, Norbert and Andrew will be available to take your questions following the presentation.